Research and development
Research & Development
Step-by-step medical platform expansion type
Mycelrix pursues R&D through a phased expansion strategy that considers both technological maturity and business risks.
After verifying the technology and process through the commercialization of mask sheets, we proceed through HA-dopa fusion topical patches and finally expand into a medical TDDS platform.
Step 1
2026 ~ 2027
Active Sheet Lineup · Super Strain (EGT Enhanced) · Functional Sheets for Different Skin Types
Step 2
2027 ~ 2029
Poly-dopa Spot Patch · Ritual Local Patch (Aroma Wellness) · Derma-Patch Lineup
Step 3
2030 ~
Medical TDDS Platform · TCM Patch (Jointly Developed with Huisong) · Lifestyle Healthcare Patch
Research on Next-Generation Functional Antimicrobial Materials — Dermcidin
2026 ~ 2027
Step 1 - Active Sheet Lineup
We verify technology and processes and secure market trust through the commercialization of mask sheet products.
At the same time, we secure a Super Strain with a significantly increased EGT content through precise editing of multinucleated fungi, and commercialize premium natural material masks and functional sheets for different skin types in which the sheet itself provides antioxidant functions without the addition of separate ingredients.
2027 ~ 2029
Step 2 - Spot Patch & Derma Patch
We are developing a HA-dopa fusion spot patch.
We are commercializing topical patches based on the concept of "adhesive high-concentration ampoules" through the Ritual topical patch (aroma wellness category) and the Derma-Patch lineup (trouble care, wrinkle improvement, whitening spot, etc.). It is a non-irritating solution that replaces the pain and irritation of existing micro-needle patches.
2027 ~ 2029
Step 3 - Medical TDDS Platform
![[복제] sustainable-business-partnership.jpg](https://static.wixstatic.com/media/a7df6f_26a28c28fd1e4c86b552ee8c257d3ffe~mv2.jpg/v1/fill/w_333,h_251,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/a7df6f_26a28c28fd1e4c86b552ee8c257d3ffe~mv2.jpg)
We are expanding into a medical TDDS platform targeting the Chinese and global markets first.
We are jointly developing a TCM (Herbal)-Loading-based transdermal Chinese medicine patch for herbal extracts and natural medicines with China's Huisong Pharmaceuticals, and are entering the global wellness market with a lineup of Lifestyle Healthcare Patches for sleep induction and menstrual pain relief. In addition, we are preparing to develop Dermcidin, a next-generation functional antimicrobial material derived from natural antimicrobial peptides from human skin that maintains antimicrobial activity even in wide pH and high-salt environments. Furthermore, based on the recombinant production technology of Mycellix researchers (published in a 2010 paper), we are pursuing the development of skin-friendly functional antimicrobial materials combined with a mycelial platform.